The main discussion in Episode #102 explores what KCAS Bio scientific advisors are hearing from customers as face-to-face visits and industry interactions increase. The conversation highlights a major shift toward more complex therapeutics and targeted delivery strategies, including conjugates, protein shuttles, in vivo gene therapies, and technologies designed to…

The main discussion in Episode #101 of “The Weekly Bioanalysis” focuses on how bioanalytical testing continues to evolve alongside increasingly complex drug modalities, with our co-hosts, Dom and John, exploring the technologies, methodologies, and regulatory trends shaping modern bioanalytical laboratories. They discuss how advances in mass spectrometry, including the…

In this special 100th episode of The Weekly Bioanalysis, hosts John Perkins and Dominic Warrino are joined on camera by KCAS Bio CEO John Bucksath and Chief Commercial Officer Amy Mize to celebrate a major milestone. Together, they reflect on the podcast’s origins during the uncertainty of the COVID-19…

On this latest episode of The Weekly Bioanalysis podcast, Dom and John dive into one of the most pressing challenges in modern bioanalysis: how to break down silos and drive better project execution through continuity across teams. Drawing from real-world experience, they explore how the industry has evolved from…

In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to…

In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and…